• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Top 5 Most-Read Articles About Automated Insulin Delivery in 2022


Content published on AJMC.com focusing on automated insulin delivery devices over the past year highlighted utilization of these devices by age, compared different types of systems, looked at barriers to uptake, and examined equity issues standing in the way of access.

Automated insulin delivery (AID) devices, sometimes called continuous glucose monitors, have revolutionized care for individuals with type 1 diabetes (T1D). Articles published on AJMC.com over the past year highlighted utilization of these devices by age, compared different types of systems, looked at barriers to uptake, and examined equity issues standing in the way of access.

Here are the most-read articles about AID in 2022.

5. Use of Continuous Glucose Monitoring Devices Varies by Age for Patients With T1D

A study published in July found that use of continuous glucose monitoring (CGM) devices varies with age for patients with T1D, with patients in middle adulthood being the most common users. CGM use was found to be associated with lower glycated hemoglobin (A1C) levels across age compared with nonuse. However, this association waned as age increased. The study was published in JAMA Network Open.

Read the full article

4. Superior T1D Control Seen With HCL Systems vs SAP Therapy in Older Adults

A multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy in older adults with T1D. It found that the HCL system was more likely to lead to superior glycemic control in a safe manner—the risk of hypoglycemia did not increase. The results were published in The Lancet: Health Longevity.

Read the full article

3. Fully Artificial Pancreas Produces Results Comparable With Hybrid Artificial Pancreas

A randomized study from Canada compared outcomes in patients living with T1D who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting. The fully artificial pancreas, which incorporated the antihyperglycemic pramlintide, produced comparable outcomes to the hybrid pancreas. Results were published in The Lancet Digital Health.

Read the full article

2. Study Reveals Limited HCP Knowledge May Hinder Use of Open-Source AID Tech

Results of a survey conducted in the United Kingdom from February through April 2019 revealed that although health care professionals are aware of the benefits of open-source AID for children and adults with T1D and would support patients who choose to use it, few are confident in their overall knowledge of the technology and awareness of its regulations. They do not discuss the potential treatment option as a result, according to the survey, which also found that 43% of the providers had concerns the technology may introduce risk of adverse outcomes if put “in the wrong hands.” The article appeared on AJMC.com in March.

Read the full article

1. Case Series Highlights Lack of Equity in T1D Care

A case series of children with T1D in California on Medicaid illustrated the need for interventions and policies that promote equitable access to diabetes technology use, including CGM devices, insulin pumps, and AID. Children have to go through hurdles that youth with private insurance do not and as a result have worse glycemic control, according to the story, which appeared in March.

Read the full article

Related Videos
dr sara horst
Mike Koroscik, MBA, MHA, Allina Health and the Allina Health Cancer Institute
Brian Mullen, PhD, head of innovation & product, The Clinic by Cleveland Clinic
Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland
dr sara horst
dr erin gillaspie
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Jennifer Sturgill, DO, Central Ohio Primary Care
Donna Fitzsimons
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy, Emory Winship Cancer Institute
Related Content
© 2023 MJH Life Sciences
All rights reserved.